Recent News

• 09.09.2025 - Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
• 09.09.2025 - Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
• 08.31.2025 - Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
• 08.31.2025 - Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
• 08.13.2025 - Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
• 08.13.2025 - Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
• 08.08.2025 - Senior Director, Assistant General Counsel, Corporate & Securities
• 08.08.2025 - Vice President & TA Head, Cardiovascular, Medical Research
• 06.16.2025 - Senior Clinical Trial Manager

Recent Filings

• 09.09.2025 - 8-K Current report
• 09.09.2025 - EX-99.1 EX-99.1
• 09.09.2025 - SC14D9C Written communication relating to third party tender offer
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 06.09.2025 - EX-99.1 EX-99.1
• 06.09.2025 - 8-K Current report